Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus
BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal of th...
Main Authors: | Clagett, B. (Author), Deeks, S.G (Author), Del Rio, C. (Author), Flexner, C. (Author), Gavegnano, C. (Author), Hardin, W.R (Author), Hunt, P.W (Author), Hurwitz, S.J (Author), Kantor, A. (Author), Lederman, M.M (Author), Lennox, J.J (Author), Marconi, V.C (Author), Moisi, D. (Author), Moser, C. (Author), Overton, E.T (Author), Schinazi, R.F (Author), Sekaly, R.-P (Author), Tressler, R. (Author), Tsibris, A. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Multiscale affinity maturation simulations to elicit broadly neutralizing antibodies against HIV
by: Chakraborty, A.K, et al.
Published: (2022) -
Ethyl 4-chloro-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate
by: Gibran Rodriguez-Vega, et al.
Published: (2019-01-01) -
Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers
by: ANRS VISCONTI Study Group, et al.
Published: (2022) -
Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers
by: ANRS VISCONTI Study Group, et al.
Published: (2022) -
Synthesis and Antimicrobial Evaluation of Novel Pyrazole, Imidazole and Pyrimidine Derivatives Possessing Imidazo[4,5-b]indol Moiety
by: Nadia Ali Ahmed Elkanzi, et al.
Published: (2019-12-01)